Cserr HF (1971) The physiology of the choroid plexus. Physiol Rev 51:273–311.
Daluge SM, Good SS, Faletto MB, Miller WH, St. Clair MH, Boone LR, Tisdale M,
Parry NR, Reardon JE, Dornsife RE, et al. (1997) 1592U89, a novel carbocyclic
nucleoside analog with potent selective anti-human immunodeficiency virus ac- tivity. Antimicrob Agents Chemother 41:1082–1093.
Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA and Brew BJ (1999) Changes to
AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS
13:1249 –1253.
Drewes LR and Gilboe DD (1977) Nutrient transport systems in dog brain. Fed Proc
36:166 –170.
Dudley MN (1995) Clinical pharmacokinetics of nucleoside antiretroviral agents.
J Infect Dis 171:S99 –S112.
Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, Abramson I, Grant
I and McCutchan JA (2000) Cerebrospinal fluid HIV RNA originates from both
local central nervous system and systemic sources. Neurology 54:927–936.
Faletto MB, Miller WH, Garvey EP, St. Clair MH, Daluge SM and Good SS (1997)
Unique intracellular activation of the potent anti-HIV agent 1592U89. Antimicrob
Agents Chemother 41:1099 –1107.
Gartner S (2000) HIV Infection and dementia. Science (Wash DC) 287:602– 604.
Groothuis D and Levy R (1997) The entry of anti-viral and anti-retroviral drugs into
the central nervous system. J Neurovirol 3:387– 400.
Hong M, Schlichter L and Bendayan R (2000) A Na -dependent nucleoside transporter in microglia. J Pharmacol Exp Ther 292:366 –374.
Hughes W, McDowell JA, Shenep J, Flynn P, Kline MW, Yogev R, Symonds W, Lou
Y and Hetherington S (1999) Safety and single-dose pharmacokinetics of abacavir
(1592U89) in human immunodeficiency virus type-1 infected children. Antimicrob
Agents Chemother 43:609 – 615.
International AIDS Society-USA (2000) Antiretroviral therapy in adults: updated
recommendations of the International AIDS Society-USA Panel. J Am Med Assoc
283:381–390.
Kumar P, Sweet DE, McDowell JE, Symonds W, Lou Y, Hetherington S and LaFon
S (1999) Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type-1 in- fected adults. Antimicrob Agents Chemother 43:603– 608.
Limoges J, Persidsky Y, Poluektova L, Rasmussen J, Ratanasuwan W, Zelivyanskaya M, McClernon DR, Lanier ER and Gendelman HE (2000) Evaluation of
antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology 54:
379 –389.
Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurements
with the Folin phenol reagent. J Biol Chem 193:265–275.
Mahony WB, Domin KL, Daluge WH, Miller WH and Zimmerman TP (1992) Enantiomeric selectivity of carbovir transport. J Biol Chem 267:19792–19797.
Mahony WB, Domin KL, Daluge WH, Miller WH and Zimmerman TP (1995) Membrane permeation characteristics of the structurally related anti-HIV agents 1592
and ( )-carbovir in human erythrocytes and human T-lymphoblastoid CD4 CEM
cells (Abstract). Proc Am Assoc Cancer Res 36:2211.
Major EO, Rausch D, Marra D and Clifford D (2000) HIV-associated dementia
Science (Wash DC) 288:440 – 441.
Marra CM and Booss J (2000) Does brain penetration of anti-HIV drugs matter? Sex
Transm Infect 76:1–5.
McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM and Stein DS (1999)
Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1
